Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 2Solid Tumors 1Sarcoma 1Neoplasm Metastasis 1Leukemia, Myeloid 1Leukemia 1Glioblastoma 1

Interventions

Cytarabine 9fludarabine 5Imatinib Mesylate 5thymoglobulin 3fludarabine phosphate 3Tacrolimus 3Sirolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Azacitidine 3zosuquidar trihydrochloride 2venetoclax 2ponatinib 2nilotinib 2enasidenib 2bosutinib 2RO6839921 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Behavior Therapy 2Antilymphocyte Serum 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1quizartinib 1plerixafor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid × glasdegib × Clear all
NCT01841333 2022-01-25

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

University of Colorado, Denver

Phase 2 Completed
31 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡